A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Clinical trial NCT02537613 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02537613
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-01
- Primary completion
- 2020-03-01
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.